ICP-248

Phase 2Small molecule

ICP-248 is one of 77 small molecule programs targeting Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic Leukemia/small Lymphocytic LymphomaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Chronic Lymphocytic Leukemia/small Lymphocytic LymphomaPhase 2/Phase 3

Active, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

189 competitors in Mantle Cell Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

82 2

Venclexta

AbbVie

Phase 3

18 3

Imbruvica

PPharmacyclics LLC.

Phase 3

37 4

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

26 5

Jaypirca

Eli Lilly

Phase 3

8 6

Treanda

AAzurity Pharmaceuticals

Phase 3

17 7

Brukinsa

BBeOne Medicines

Phase 3

16 8

Oncovin

EEastern Cooperative Oncology Group

Phase 3

11 9

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

6 10

Beqalzi

BBeOne Medicines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Mature B-Cell Malignancies

NCT05728658

Q4 2027

Phase 1Recruiting

Anti-CD20 Monoclonal Antibody

NCT06351527

Q1 2028

Phase 1Recruiting

Myeloid Malignancies

NCT06656494

Q3 2028

Phase 2Recruiting

Mantle Cell Lymphoma

NCT07082686

Clinical

Trials by Indication[1]

Myeloid Malignancies1 trial

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1·NCT06656494·266 enrolled

Mature B-cell Malignancies1 trial

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1·NCT05728658·191 enrolled

Anti-CD20 Monoclonal Antibody1 trial

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Recruiting·IInnoCare Pharma Inc.·Phase 1·NCT06351527·78 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2/3·NCT06378138·226 enrolled

Mantle Cell Lymphoma1 trial

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT07082686·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ICP-248. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICP-248 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICP-248. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing InnoCare Pharma Tech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBeijing InnoCare Pharma Tech Co., Ltd.

ICP-248

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q3 2028

Trials by Indication[1]

Myeloid Malignancies1 trial

Mature B-cell Malignancies1 trial

Anti-CD20 Monoclonal Antibody1 trial

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Mantle Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News